• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Synosia Therapeutics AG - Product Pipeline Review - Q4 2010 Product Image

Synosia Therapeutics AG - Product Pipeline Review - Q4 2010

  • ID: 1463969
  • December 2010
  • 42 pages
  • Global Markets Direct

Synosia Therapeutics AG – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Synosia Therapeutics AG - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Synosia Therapeutics AG - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Synosia Therapeutics AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination READ MORE >



List of Tables
List of Figures
Synosia Therapeutics AG Snapshot
Synosia Therapeutics AG Overview
Key Information
Key Facts
Synosia Therapeutics AG – Research and Development Overview
Key Therapeutic Areas
Synosia Therapeutics AG – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Synosia Therapeutics AG – Pipeline Products Glance
Synosia Therapeutics AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Synosia Therapeutics AG – Drug Profiles
Nepicastat
Product Description
Mechanism of Action
R&D Progress
SYN-111
Product Description
Mechanism of Action
R&D Progress
SYN-111
Product Description
Mechanism of Action
R&D Progress
SYN-114
Product Description
Mechanism of Action
R&D Progress
SYN-120
Product Description
Mechanism of Action
R&D Progress
Synosia Therapeutics AG – Pipeline Analysis
Synosia Therapeutics AG – Pipeline Products by Therapeutic Class
Synosia Therapeutics AG Pipeline Products By Target
Synosia Therapeutics AG – Pipeline Products by Route of Administration
Synosia Therapeutics AG – Pipeline Products by Molecule Type
Synosia Therapeutics AG - Dormant Projects
Synosia Therapeutics AG – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jul 19, 2010: Eisai Reports FDA's Acceptance Of BANZEL Oral Suspension NDA For Review
May 07, 2010: Eisai To Initiate Japan Clinical Trial Of Rufinamide In Lennox-Gastaut Syndrome Patients
May 13, 2009: Synosia Therapeutics Begins Phase I Trial Of A New Generation Treatment For Cognitive Impairment
May 13, 2009: Synosia Therapeutics Begins Phase I Trial Of A New Generation Treatment For Cognitive Impairment
May 13, 2009: Synosia Therapeutics Begins Phase I Trial Of A New Generation Treatment For Cognitive Impairment
Mar 10, 2009: Synosia Therapeutics Announces Second Agreement With Roche (RHHBY)
Jul 24, 2008: US Department Of Defense To Fund Phase II Trial Of Synosia Therapeutics Nepicastat For Post-Traumatic Stress Disorder
Apr 01, 2008: Synosia Therapeutics Starts Phase II Efficacy Trial For Rufinamide
Mar 31, 2008: Synosia Begins With The Phase II Efficacy Study For Rufinamide
Jan 22, 2008: Synosia Therapeutics Announces Encouraging Results Of Proof-Of-Concept Clinical Trial For Epilepsy Drug
Financial Deals Landscape
Synosia Therapeutics AG, Deals Volume Summary, 2004 to YTD 2010
Synosia Therapeutics AG, Deals Summary By Region, 2004 to YTD 2010
Synosia Therapeutics AG, Deals Summary, 2004 to YTD 2010
Synosia Therapeutics AG Detailed Deal Summary
Venture Financing
Synosia Therapeutics Secures $29 Million In Series B Financing
Synosia Therapeutics Secures $30 Million In Series A Financing
Synosia Therapeutics Enters Into An Agreement With Roche
Synosis Therapeutics Enters Into An Agreement With Roche
Licensing Agreements
Synosia Therapeutics Enters Into Licensing Agreement With Syngenta
Synosia Therapeutics Enters Into Licensing Agreement With Novartis Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS